Isotretinoin: experts convene to investigate new concerns over suicide riskBMJ 2019; 367 doi: https://doi.org/10.1136/bmj.l7085 (Published 31 December 2019) Cite this as: BMJ 2019;367:l7085
- Elisabeth Mahase
- The BMJ
An expert group has been reconvened to review recent safety data relating to the acne drug isotretinoin (marketed as Roaccutane) and evaluate the risk of sexual and psychiatric adverse effects, including suicide.
The Medicines and Healthcare Products Regulatory Agency’s isotretinoin expert working group had looked at the risk of psychiatric adverse reactions suspected to be associated with isotretinoin in 2014, but it has now reformed to look at more recently reported adverse reactions. In 2019 12 deaths were recorded among people to whom isotretinoin had been prescribed, 10 by suicide, MHRA data …